

Brian M Alexander

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9050081/publications.pdf>

Version: 2024-02-01

170
papers

9,468
citations

44069

48
h-index

45317

90
g-index

173
all docs

173
docs citations

173
times ranked

14271
citing authors

#	ARTICLE	IF	CITATIONS
1	The use of external control data for predictions and futility interim analyses in clinical trials. <i>Neuro-Oncology</i> , 2022, 24, 247-256.	1.2	29
2	Multimodal platform for assessing drug distribution and response in clinical trials. <i>Neuro-Oncology</i> , 2022, 24, 64-77.	1.2	4
3	A molecularly integrated grade for meningioma. <i>Neuro-Oncology</i> , 2022, 24, 796-808.	1.2	83
4	The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2022, 28, 728-737.	7.0	20
5	Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects. <i>Nature Communications</i> , 2022, 13, 873.	12.8	13
6	Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Network Open</i> , 2022, 5, e225394.	5.9	37
7	Association of <i>CD274</i> (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2022, 27, 732-739.	3.7	5
8	Optimality of testing procedures for survival data in the nonproportional hazards setting. <i>Biometrics</i> , 2021, 77, 587-598.	1.4	5
9	Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response. <i>Cancer Discovery</i> , 2021, 11, 282-292.	9.4	132
10	A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases. <i>Modern Pathology</i> , 2021, 34, 252-263.	5.5	78
11	CYLD mutation characterizes a subset of HPV-positive head and neck squamous cell carcinomas with distinctive genomics and frequent cylindroma-like histologic features. <i>Modern Pathology</i> , 2021, 34, 358-370.	5.5	12
12	Feasibility of hippocampal avoidance whole brain radiation in patients with hippocampal involvement: Data from a prospective study. <i>Medical Dosimetry</i> , 2021, 46, 21-28.	0.9	4
13	KMDATA: a curated database of reconstructed individual patient-level data from 153 oncology clinical trials. <i>Database: the Journal of Biological Databases and Curation</i> , 2021, 2021, .	3.0	1
14	FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab017.	0.7	6
15	Optimized EGFR Blockade Strategies in <i>EGFR</i> Addicted Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 3126-3140.	7.0	11
16	The effects of releasing early results from ongoing clinical trials. <i>Nature Communications</i> , 2021, 12, 801.	12.8	4
17	Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms. <i>Clinical Cancer Research</i> , 2021, 27, 3094-3105.	7.0	101
18	Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer to identify targetable BRCA alterations and AR resistance mechanisms.. <i>Journal of Clinical Oncology</i> , 2021, 39, 25-25.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry. <i>Pathology and Oncology Research</i> , 2021, 27, 592997.	1.9	11
20	Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials. <i>JAMA Network Open</i> , 2021, 4, e213304.	5.9	4
21	Comprehensive molecular profiling of pleural mesothelioma according to histologic subtype.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8555-8555.	1.6	0
22	Patient with Lobular Carcinoma of the Breast and Activating AKT1 E17K Variant. <i>Acta Medica Academica</i> , 2021, 50, 209.	0.8	2
23	Real-world association of HER2/ <i>ERBB2</i> concordance with trastuzumab clinical benefit in advanced esophagogastric cancer. <i>Future Oncology</i> , 2021, 17, 4101-4114.	2.4	7
24	Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns. <i>JCO Precision Oncology</i> , 2021, 5, 1354-1376.	3.0	12
25	Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma. <i>JCO Precision Oncology</i> , 2021, 5, 1285-1296.	3.0	8
26	Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors. <i>Translational Oncology</i> , 2021, 14, 101184.	3.7	13
27	Leveraging external data in the design and analysis of clinical trials in neuro-oncology. <i>Lancet Oncology</i> , The, 2021, 22, e456-e465.	10.7	53
28	Comprehensive genomic profiling of histologic subtypes of urethral carcinomas. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 731.e1-731.e15.	1.6	7
29	CTNI-05. PRELIMINARY RESULTS OF THE NERATINIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. <i>Neuro-Oncology</i> , 2021, 23, vi59-vi59.	1.2	4
30	Atypical Histopathological Features and the Risk of Treatment Failure in Nonmalignant Meningiomas: A Multi-Institutional Analysis. <i>World Neurosurgery</i> , 2020, 133, e804-e812.	1.3	4
31	New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures. <i>Alzheimer's and Dementia</i> , 2020, 16, 131-143.	0.8	45
32	The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1021-1029.	6.3	138
33	Meta-Analysis of PD-L1 Expression As a Predictor of Survival After Checkpoint Blockade. <i>JCO Precision Oncology</i> , 2020, 4, 1196-1206.	3.0	9
34	Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. <i>PLoS ONE</i> , 2020, 15, e0237802.	2.5	223
35	<i>CDKN2C</i> -Null Leiomyosarcoma: A Novel, Genomically Distinct Class of <i>TP53</i> / <i>RB1</i> Wild-Type Tumor With Frequent <i>CIC</i> Genomic Alterations and 1p/19q-Codeletion. <i>JCO Precision Oncology</i> , 2020, 4, 955-971.	3.0	6
36	Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer. <i>Oncologist</i> , 2020, 25, 943-953.	3.7	19

#	ARTICLE	IF	CITATIONS
37	Genomic Profiling of Circulating Tumor DNA From Cerebrospinal Fluid to Guide Clinical Decision Making for Patients With Primary and Metastatic Brain Tumors. <i>Frontiers in Neurology</i> , 2020, 11, 544680.	2.4	16
38	Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors. <i>JAMA Network Open</i> , 2020, 3, e2025109.	5.9	92
39	Evidence-Based Development and Clinical Use of Precision Oncology Therapeutics. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 440-443.	4.7	4
40	Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling. <i>Lung Cancer</i> , 2020, 148, 69-78.	2.0	25
41	Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 716-724.	0.8	7
42	Pan-Cancer Analysis of <i>BRCA1</i> and <i>BRCA2</i> Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. <i>JCO Precision Oncology</i> , 2020, 4, 442-465.	3.0	103
43	CYLD-mutant cylindroma-like basaloid carcinoma of the anus: a genetically and morphologically distinct class of HPV-related anal carcinoma. <i>Modern Pathology</i> , 2020, 33, 2614-2625.	5.5	9
44	Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the <i>ALK</i> Gene Have Durable Responses to ALK Kinase Inhibitors. <i>Lung Cancer: Targets and Therapy</i> , 2020, Volume 11, 33-39.	2.7	2
45	Retinoblastoma protein expression and its predictors in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 19.	5.2	23
46	Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations. <i>Modern Pathology</i> , 2020, 33, 2397-2406.	5.5	16
47	Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1-KMT2A and VIM-KMT2A fusions. <i>Modern Pathology</i> , 2020, 33, 2307-2317.	5.5	24
48	Vulvar Squamous Cell Carcinoma: Comprehensive Genomic Profiling of HPV+ Versus HPV- Forms Reveals Distinct Sets of Potentially Actionable Molecular Targets. <i>JCO Precision Oncology</i> , 2020, 4, 647-661.	3.0	21
49	Hospice Utilization in Elderly Patients With Brain Metastases. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1251-1258.	6.3	7
50	Racial disparities in supportive medication use among older patients with brain metastases: a population-based analysis. <i>Neuro-Oncology</i> , 2020, 22, 1339-1347.	1.2	27
51	Melanomas with activating RAF1 fusions: clinical, histopathologic, and molecular profiles. <i>Modern Pathology</i> , 2020, 33, 1466-1474.	5.5	28
52	Neurologic Complications of Cranial Radiation Therapy and Strategies to Prevent or Reduce Radiation Toxicity. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 34.	4.2	17
53	Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. <i>Clinical Cancer Research</i> , 2020, 26, 2838-2848.	7.0	403
54	Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. <i>European Urology</i> , 2020, 77, 548-556.	1.9	41

#	ARTICLE	IF	CITATIONS
55	Urothelial cancer harbours <i>EGFR</i> and <i>HER2</i> amplifications and exon 20 insertions. <i>BJU International</i> , 2020, 125, 739-746.	2.5	14
56	A quantitative framework for modeling COVID-19 risk during adjuvant therapy using published randomized trials of glioblastoma in the elderly. <i>Neuro-Oncology</i> , 2020, 22, 918-927.	1.2	15
57	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	1.2	543
58	Primary versus metastatic intrahepatic cholangiocarcinoma: A comparative comprehensive genomic profiling (CGP) study. <i>Journal of Clinical Oncology</i> , 2020, 38, 578-578.	1.6	4
59	PD-L1 expression, tumor mutational burden, and microsatellite instability status in 746 pancreas ductal adenocarcinomas. <i>Journal of Clinical Oncology</i> , 2020, 38, 757-757.	1.6	2
60	PATH-16. COMPREHENSIVE GENOMIC PROFILING ACCURATELY DETERMINES 1p19q CODELETION STATUS IN GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, ii167-ii167.	1.2	0
61	Barriers to accrual and enrollment in brain tumor trials. <i>Neuro-Oncology</i> , 2019, 21, 1100-1117.	1.2	36
62	Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data. <i>Clinical Cancer Research</i> , 2019, 25, 4993-5001.	7.0	57
63	To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs. <i>Neuro-Oncology</i> , 2019, 21, 1239-1249.	1.2	16
64	Association of Neurosurgical Resection With Development of Pachymeningeal Seeding in Patients With Brain Metastases. <i>JAMA Oncology</i> , 2019, 5, 703.	7.1	63
65	Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGHT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	46
66	Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 171-179.	2.5	15
67	Local control after brain-directed radiation in patients with cystic versus solid brain metastases. <i>Journal of Neuro-Oncology</i> , 2019, 142, 355-363.	2.9	13
68	Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications. <i>Clinical Cancer Research</i> , 2019, 25, 6339-6345.	7.0	48
69	The impact of histopathology and NAB2-STAT6 fusion subtype in classification and grading of meningeal solitary fibrous tumor/hemangiopericytoma. <i>Acta Neuropathologica</i> , 2019, 137, 307-319.	7.7	44
70	The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 142-151.	0.8	118
71	Neurosurgical Resection and Stereotactic Radiation Versus Stereotactic Radiation Alone in Patients with a Single or Solitary Brain Metastasis. <i>World Neurosurgery</i> , 2019, 122, e1557-e1561.	1.3	17
72	Immunotherapy predictive biomarkers in metastatic breast cancer (MBC). <i>Journal of Clinical Oncology</i> , 2019, 37, 1023-1023.	1.6	2

#	ARTICLE	IF	CITATIONS
73	Adenocarcinoma (ACB), urothelial carcinoma (UCB) and squamous cell carcinoma (SCCB) of the bladder: A Comprehensive Genomic Profiling (CGP) Study.. Journal of Clinical Oncology, 2019, 37, 4533-4533.	1.6	1
74	Metastatic penile (mPSCC), uterine cervical (mCSCC), and skin (mSSCC) squamous cell carcinomas: A comparative genomic profiling (CGP) study.. Journal of Clinical Oncology, 2019, 37, 4585-4585.	1.6	1
75	Analysis of HER2 mutant bladder urothelial carcinomas reveals unique mutational signature.. Journal of Clinical Oncology, 2019, 37, 460-460.	1.6	0
76	Malignant pheochromocytoma (MP): A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2019, 37, 4584-4584.	1.6	0
77	Extra-mammary Paget's disease (EMPD) of the skin: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2019, 37, 9591-9591.	1.6	1
78	FGFR2: A pan-genomic target.. Journal of Clinical Oncology, 2019, 37, 3099-3099.	1.6	2
79	Anal melanoma: A comparative comprehensive genomic profiling study.. Journal of Clinical Oncology, 2019, 37, 9566-9566.	1.6	0
80	Acid-Based Decalcification Methods Compromise Genomic Profiling from DNA and RNA. Blood, 2019, 134, 4659-4659.	1.4	3
81	Loss of Heterozygosity of FLT3-ITD Is Common in Acute Myeloid Leukemia and May be a More Consistent Prognostic Marker Than FLT3-ITD Allele Frequency. Blood, 2019, 134, 1437-1437.	1.4	2
82	The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?. Neuro-Oncology, 2018, 20, 1034-1043.	1.2	100
83	Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. Lancet Oncology, The, 2018, 19, e240-e251.	10.7	108
84	Meningioma transcription factors link cell lineage with systemic metabolic cues. Neuro-Oncology, 2018, 20, 1331-1343.	1.2	9
85	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro-Oncology, 2018, 20, 1240-1250.	1.2	64
86	Platform trials arrive on time for glioblastoma. Neuro-Oncology, 2018, 20, 723-725.	1.2	14
87	Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. Radiotherapy and Oncology, 2018, 126, 511-518.	0.6	18
88	Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncology, The, 2018, 19, e33-e42.	10.7	42
89	Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation. JAMA Oncology, 2018, 4, 1123.	7.1	238
90	The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. Neuro-Oncology, 2018, 20, 1162-1172.	1.2	92

#	ARTICLE	IF	CITATIONS
91	Hazards of Hazard Ratios “ Deviations from Model Assumptions in Immunotherapy. <i>New England Journal of Medicine</i> , 2018, 378, 1158-1159.	27.0	79
92	Innovation Incentives and Biomarkers. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 34-36.	4.7	14
93	Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. <i>Clinical Cancer Research</i> , 2018, 24, 737-743.	7.0	154
94	INNV-13. ALLELE: A CONSORTIUM FOR PROSPECTIVE GENOMICS AND FUNCTIONAL DIAGNOSTICS TO GUIDE PATIENT CARE AND TRIAL ANALYSIS IN NEWLY-DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi140-vi141.	1.2	0
95	PATH-08. THE IVY GLIOBLASTOMA PATIENT ATLAS - A NOVEL CLINICAL AND RADIO-GENOMICS RESOURCE FOR EARLY PHASE CLINICAL TRIAL DESIGN AND INTERPRETATION. <i>Neuro-Oncology</i> , 2018, 20, vi159-vi159.	1.2	0
96	TMOD-14. A PATIENT-DERIVED CANCER CELL LINE ATLAS OF PRIMARY AND METASTATIC CENTRAL NERVOUS SYSTEM TUMORS. <i>Neuro-Oncology</i> , 2018, 20, vi271-vi271.	1.2	0
97	PDTM-06. ALK AMPLIFICATION AND REARRANGEMENTS ARE RECURRENT TARGETABLE EVENTS IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi204-vi205.	1.2	3
98	RARE-08. GRADING CONSIDERATIONS FOR MENINGEAL SOLITARY FIBROUS TUMOR/HEMANGIOPERICYTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi237-vi238.	1.2	1
99	Bayesian Adaptive Randomization in Dose-Finding Trials. <i>JAMA Network Open</i> , 2018, 1, e186075.	5.9	2
100	Implications of Screening for Brain Metastases in Patients With Breast Cancer and Non-“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 1001.	7.1	44
101	Neurologic Complications of Radiation Therapy. <i>Neurologic Clinics</i> , 2018, 36, 599-625.	1.8	18
102	ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2003-2003.	1.6	1
103	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. <i>Neuro-Oncology</i> , 2017, 19, now235.	1.2	99
104	Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. <i>Neuro-Oncology</i> , 2017, 19, 109-117.	1.2	211
105	Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab. <i>Neuro-Oncology</i> , 2017, 19, 1688-1697.	1.2	84
106	Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. <i>Neuro-Oncology</i> , 2017, 19, 1511-1521.	1.2	483
107	Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, 469-474.	1.2	34
108	Whole brain radiotherapy for non-small cell lung cancer. <i>Lancet, The</i> , 2017, 389, 1394-1395.	13.7	2

#	ARTICLE	IF	CITATIONS
109	Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, 908-917.	1.2	23
110	Brain Metastases in Newly Diagnosed Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1069.	7.1	224
111	Future cancer research priorities in the USA: a Lancet Oncology Commission. <i>Lancet Oncology</i> , The, 2017, 18, e653-e706.	10.7	153
112	Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. <i>Journal of Neuro-Oncology</i> , 2017, 135, 581-591.	2.9	15
113	Prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer. <i>Neuro-Oncology</i> , 2017, 19, 1015-1016.	1.2	1
114	The cost and value of glioblastoma therapy. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 657-659.	2.4	10
115	Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. <i>Radiotherapy and Oncology</i> , 2017, 124, 98-103.	0.6	51
116	Designing Clinical Trials That Accept New Arms: An Example in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3160-3168.	1.6	28
117	Adult Glioblastoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2402-2409.	1.6	561
118	Radiographic Prediction of Meningioma Grade and Genomic Profile. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2017, 78, S1-S156.	0.8	1
119	Radiographic prediction of meningioma grade by semantic and radiomic features. <i>PLoS ONE</i> , 2017, 12, e0187908.	2.5	109
120	Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. <i>Journal of Neuro-Oncology</i> , 2016, 129, 389-393.	2.9	7
121	Updates in the management of brain metastases. <i>Neuro-Oncology</i> , 2016, 18, 1043-1065.	1.2	209
122	Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2016, 2, 16002.	5.2	31
123	Steroid and anticonvulsant prophylaxis for stereotactic radiosurgery: Large variation in physician recommendations. <i>Practical Radiation Oncology</i> , 2016, 6, e89-e96.	2.1	14
124	Defining optimal initial therapy for primary CNS lymphoma. <i>Lancet Haematology</i> , the, 2016, 3, e206-e207.	4.6	3
125	A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. <i>Neuro-Oncology</i> , 2016, 18, 849-854.	1.2	45
126	Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. <i>Nature Medicine</i> , 2016, 22, 723-726.	30.7	105

#	ARTICLE	IF	CITATIONS
127	Evaluation of initial setup accuracy and intrafraction motion for spine stereotactic body radiation therapy using stereotactic body frames. <i>Practical Radiation Oncology</i> , 2016, 6, e17-e24.	2.1	16
128	Genomic landscape of intracranial meningiomas. <i>Journal of Neurosurgery</i> , 2016, 125, 525-535.	1.6	104
129	Oncogenic PI3K mutations are as common as <i>AKT1</i> and <i>SMO</i> mutations in meningioma. <i>Neuro-Oncology</i> , 2016, 18, 649-655.	1.2	221
130	Preclinical Efficacy of the MDM2 Inhibitor RG7112 in <i>MDM2</i> -Amplified and <i>TP53</i> Wild-type Glioblastomas. <i>Clinical Cancer Research</i> , 2016, 22, 1185-1196.	7.0	89
131	MAPK activation and <i>HRAS</i> mutation identified in pituitary spindle cell oncocytoma. <i>Oncotarget</i> , 2016, 7, 37054-37063.	1.8	27
132	Functional profiling of a glioblastoma (GBM) patient-derived cell line (PDCL) panel to identify cell-intrinsic differential radiation response.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2069-2069.	1.6	0
133	Fully automatic GBM segmentation in the TCGA-GBM dataset: Prognosis and correlation with VASARI features. <i>Scientific Reports</i> , 2015, 5, 16822.	3.3	78
134	Ipilimumab and cranial radiation in metastatic melanoma patients: a case series and review. , 2015, 3, 50.		84
135	Getting it first versus getting it right: weighing the value of and evidence for progression-free survival as a surrogate endpoint for overall survival in glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 765-766.	1.2	3
136	Extent of resection and overall survival for patients with atypical and malignant meningioma. <i>Cancer</i> , 2015, 121, 4376-4381.	4.1	144
137	Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials. <i>Neuro-Oncology</i> , 2015, 17, 1106-1113.	1.2	21
138	Hypofractionated Versus Standard Radiation Therapy With or Without Temozolomide for Older Glioblastoma Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 384-389.	0.8	46
139	Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation. <i>Journal of Neuro-Oncology</i> , 2015, 124, 137-146.	2.9	12
140	A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3610-3618.	7.0	79
141	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1344-1355.	1.2	40
142	Somatic mutations associated with MRI-derived volumetric features in glioblastoma. <i>Neuroradiology</i> , 2015, 57, 1227-1237.	2.2	79
143	Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. <i>Neuro-Oncology</i> , 2015, 17, 1188-98.	1.2	346
144	Salvage whole brain radiotherapy or stereotactic radiosurgery after initial stereotactic radiosurgery for 1-4 brain metastases. <i>Journal of Neuro-Oncology</i> , 2015, 124, 429-437.	2.9	13

#	ARTICLE	IF	CITATIONS
145	A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. <i>Oncolmmunology</i> , 2015, 4, e1046028.	4.6	191
146	In Reply to Levra etÂal. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 218-219.	0.8	0
147	Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group. <i>Neuro-Oncology</i> , 2015, 17, 180-188.	1.2	28
148	Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. <i>Oncotarget</i> , 2014, 5, 10596-10606.	1.8	65
149	Progression-free survival: too much risk, not enough reward?. <i>Neuro-Oncology</i> , 2014, 16, 615-616.	1.2	16
150	The role of whole brain radiation therapy in the management of melanoma brain metastases. <i>Radiation Oncology</i> , 2014, 9, 143.	2.7	26
151	Local control after fractionated stereotactic radiation therapy for brain metastases. <i>Journal of Neuro-Oncology</i> , 2014, 120, 339-346.	2.9	37
152	Cancer-Specific Outcomes Among Young Adults Without Health Insurance. <i>Journal of Clinical Oncology</i> , 2014, 32, 2025-2030.	1.6	112
153	Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. <i>Neuro-Oncology</i> , 2014, 16, 1523-1529.	1.2	22
154	Autophagy Is Critical for Pancreatic Tumor Growth and Progression in Tumors with p53 Alterations. <i>Cancer Discovery</i> , 2014, 4, 905-913.	9.4	395
155	Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. <i>Neuro-Oncology</i> , 2014, 16, 1547-1553.	1.2	80
156	Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival. <i>Lung Cancer</i> , 2014, 85, 239-244.	2.0	82
157	Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. <i>Oncotarget</i> , 2014, 5, 8083-8092.	1.8	55
158	Current and future directions for Phase II trials in high-grade glioma. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 369-387.	2.8	4
159	A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806). <i>Journal of Neuro-Oncology</i> , 2013, 111, 33-39.	2.9	15
160	Enhancing radiation therapy for patients with glioblastoma. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 569-581.	2.4	14
161	Biomarker-based adaptive trials for patients with glioblastoma-lessons from I-SPY 2. <i>Neuro-Oncology</i> , 2013, 15, 972-978.	1.2	37
162	Bayesian Adaptive Randomized Trial Design for Patients With Recurrent Glioblastoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 3258-3263.	1.6	104

#	ARTICLE	IF	CITATIONS
163	DNA Repair Biomarkers Predict Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 164-171.	0.8	39
164	Importance of Extracranial Disease Status and Tumor Subtype for Patients Undergoing Radiosurgery for Breast Cancer Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2012, 83, e479-e486.	0.8	24
165	Salvage stereotactic radiosurgery for breast cancer brain metastases. Cancer, 2012, 118, 2014-2020.	4.1	29
166	Targeting DNA repair and the cell cycle in glioblastoma. Journal of Neuro-Oncology, 2012, 107, 463-477.	2.9	32
167	Tumor Volume Is a Prognostic Factor in Non-Small-Cell Lung Cancer Treated With Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1381-1387.	0.8	64
168	Role of isocitrate dehydrogenase in glioma. Expert Review of Neurotherapeutics, 2011, 11, 1399-1409.	2.8	15
169	DNA Repair Protein Biomarkers Associated with Time to Recurrence in Triple-Negative Breast Cancer. Clinical Cancer Research, 2010, 16, 5796-5804.	7.0	32
170	DNA repair inhibition in anti-cancer therapeutics. , 0, , 936-944.		0